TrialThe Lancet. Oncology2019

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.

Ian Judson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.